HDAC inhibitors as single agents, via modulation of HDAC1, HDAC3, HDAC8 and HDAC10 function, increased the expression of MHCA and decreased the expression of PD-L1, PD-L2 and ODC on tumor cells. The gene discussed is HDAC3; the disease is neoplasm.